LONDON, GROSSBRITANNIEN10. FEBRUAR 2020QUELLE: AFPTV1. Halbnahe Dr Paul McKay at work2. Nah Dr Paul McKay at work3. Halbnahe Dr Paul McKay at work4. Totale Dr Paul McKay entering lab5. O-TON 1 - Dr Paul McKay, Senior Researcher, Imperial College London (Mann, English, 18 Sek.): 'So at the moment we have just put the vaccine that we’ve generated from these bacteria into mice, and we’re hoping that over the next few weeks we’ll be able to determine the response that we can see in those mice, in their blood, their antibody response to the coronavirus.' 6. Zwischenschnitt: Totale 'bio-hazard' sign 7. Nah Dr Paul McKay looking at bacterial samples growing vaccine8. Totale Dr Paul McKay looking at bacterial samples growing vaccine9. Halbnahe researcher at work10. O-TON 2 - Dr Paul McKay, Senior Researcher, Imperial College London (Mann, English, 18 Sek.): 'Once the phase one trial Is complete - which can take a few months to complete - it can be immediately started into an efficacy trial in people, which will also take a few months to complete. So perhaps by the end of this year there will be a viable tested vaccine that would be suitable for use in people.' 11. Zwischenschnitt: Totale from Dr Paul McKay at microscope to sample 12. Totale Dr Paul McKay at microscope13. Nah computer screen showing scan of RNA14. Bildsequenz Dr Paul McKay saying 'So here we have a long piece of RNA, and this is the RNA that is going to be used in animal studies as the vaccine, and it shows that it's intact and it's of good quality for animal experiments'